ArticleJournal for immunotherapy of cancer2025

Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects.

Michela Capello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.